{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T14:14:34Z","timestamp":1783260874438,"version":"3.54.6"},"reference-count":13,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology & Therapeutics"],"abstract":"\n Background:<\/jats:title>\n The rising incidence of early-onset type 2 diabetes (T2D) has made it the leading cause of pregestational diabetes worldwide. However, real-world data on glycemic control during pregnancy and its association with perinatal outcomes remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To examine associations between continuous glucose monitoring (CGM)-derived metrics and perinatal outcomes throughout pregnancy and across gestational windows in women with T2D.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n We conducted a single-center retrospective cohort study including all pregnant women with T2D who delivered between January 2020 and August 2025 and used CGM for \u22657 days (\n n<\/jats:italic>\n = 80). The primary composite outcome included preterm birth (<37 weeks), large-for-gestational-age infant, neonatal hypoglycemia, shoulder dystocia, neonatal intensive care admission, hyperbilirubinemia, or perinatal mortality. CGM metrics included mean glucose, time in range (TIR\n 63\u2013140<\/jats:sub>\n ), time below range, and glucose coefficient of variation. Associations were assessed using mean differences and adjusted logistic regression.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Among 80 women (mean (\u00b1standard deviation) age 34 \u00b1 6 years; body mass index 33 \u00b1 7 kg\/m\n 2<\/jats:sup>\n ; glycated hemoglobin 7.4% \u00b1 1.7%), 24 (30%) were diagnosed during pregnancy. Median (interquartile range) CGM use was 118 (69\u2013187) days. Mean TIR\n 63\u2013140<\/jats:sub>\n was 72% \u00b1 13%; 50 (63%) women achieved TIR\n 63\u2013140<\/jats:sub>\n \u226570%, 19 (24%) achieved \u226580%, and only 5 (6%) achieved the \u226590% target. Perinatal events occurred in 53 (66%) women. Mean glucose was higher (+11 mg\/dL; 95% confidence interval [CI], +5 to +16) and TIR lower (\u20138.1 percentage points; 95% CI, \u201313.2 to \u20133.0) in women with events, with differences apparent from 9 to 12 weeks of gestation. Each 10-point decrease in TIR\n 63\u2013140<\/jats:sub>\n was associated with higher odds of perinatal events (adjusted odds ratio 1.82; 95% CI, 1.19\u20133.00). No significant differences were observed for other CGM-derived metrics.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In women with T2D, poorer CGM-assessed glycemic control was associated with perinatal events from early pregnancy. Few women achieved the recommended glycemic targets, highlighting the need for improved management and prevention.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/15209156261466873","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:57:11Z","timestamp":1783058231000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous Glucose Monitoring Metrics and Perinatal Outcomes in Pregnant Women with Type 2 Diabetes"],"prefix":"10.1177","author":[{"given":"Angel","family":"Chemoul","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soulaima","family":"Trigui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ciofu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Neizelien","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Penfornis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."},{"name":"Paris-Saclay University, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7592","authenticated-orcid":false,"given":"Coralie","family":"Amadou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France."},{"name":"Paris-Saclay University, Corbeil-Essonnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072385"},{"key":"e_1_3_4_3_1","unstructured":"2.NHS Digital. National Pregnancy in Diabetes Audit. n.d. Available from: https:\/\/digital.nhs.uk\/data-and-information\/clinical-audits-and-registries\/national-pregnancy-in-diabetes-audit [Last accessed: September30 2025]."},{"key":"e_1_3_4_4_1","unstructured":"3.INSERM. National Perinatal Survey 2021 Report \u2013 French National Perinatal Surveys. n.d. Available from: https:\/\/enp.inserm.fr\/en\/national-perinatal-survey-2021-report\/ [Last accessed: November16 2025]."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.11.026"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0300"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.16140"},{"key":"e_1_3_4_8_1","unstructured":"7.AUDIPOG. Courbes de Morphom\u00e9trie Standard. n.d. Available from: https:\/\/www.audipog.net\/Courbes-morpho [Last accessed: September30 2025]."},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2494"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005609"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00225-5"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0636"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2025.101669"}],"container-title":["Diabetes Technology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261466873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156261466873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261466873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T13:20:39Z","timestamp":1783257639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156261466873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":13,"alternative-id":["10.1177\/15209156261466873"],"URL":"https:\/\/doi.org\/10.1177\/15209156261466873","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"15209156261466873"}}